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During the last two decades, the CHOP regimen is considered to
be the standard treatment for intermediate or high-grade non-
Hodgkin lymphoma (NHL). In recent years, however, several
schemes of more aggressive chemotherapy (e.g. the so-called third
generation regimens) have been devised and tested both in
controlled and uncontrolled clinical studies. These schemes of
aggressive chemotherapy have been reported to increase the
response rate on the short-term, but have an uncertain impact on
long-term survival (Martelli et al, 1997). 
There are numerous Phase II studies reporting the results with
third generation chemotherapy, but these do not permit to define the
therapeutic role of these new regimens in comparison with CHOP.
On the other hand, the results of Phase-III randomized trials evalu-
ating third generation schemes vs. CHOP (Gordon et al, 1992;
Fisher et al, 1993; Cooper et al, 1994; Montserrat et al, 1996; Wolf
et al, 1997; Jerkeman et al, 1999) have never been included in a
systematic overview or in a meta-analysis. 
In the present study, we conducted a meta-analysis of the
survival data obtained in randomized controlled trials (RCTs)
comparing third generation regimes with CHOP. 
METHODS 
Study design 
The aim of our study was to evaluate survival for the two
following therapeutic options for patients with intermediate or
high grade NHL: a) third generation regimens (namely MACOP-B
or m-BACOD or ProMace-CytaBOM or any other regimen which
the author of the trial originally defined as third generation); b)
CHOP. Our analysis consisted of two sequential phases: 1)
Literature search of the RCTs that evaluated survival for these two
therapeutic options; 2) Survival analysis with meta-analytic pooling
of the results from the pertinent trials and with statistical testing. 
Our survival meta-analysis was carried out through the
following procedure. Firstly, the patient-level information on
survival was retrieved from the cohorts enrolled in the various
studies; subsequently, the survival difference between third
generation regimens and CHOP was assessed by pooling the indi-
vidual data of survival across the pertinent studies and by
constructing the two survival curves for third generation regimens
and CHOP. 
Literature search 
This part of our study included: 
l a MEDLINE search on the Internet (WWW Entrez, PubMed
Data Base, Internet address:
‘http://www4.ncbi.nlm.nih.gov/PubMed/’, search from 
1 January 1970 to 29 February 2000, keywords: 
‘non-Hodgkin’, ‘survival’ and ‘randomized’ or ‘randomised’); 
l a search on the IDIS compact-disk (Iowa Drug Information
System, Iowa City, USA; computer search from January 1985
to December 1999; keywords: ‘non-Hodgkin’, ‘survival’ and
‘randomized’ or ‘randomised’); 
l consultation of reviews, textbooks and experts in this partic-
ular field of study. 
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doi: 10.1054/ bjoc.2000.1566, available online at http://www.idealibrary.com on  http://www.bjcancer.comIn addition, we reviewed all the references listed in the trials we
found. Only the trials published in English were considered. 
Meta-analysis of survival data 
The studies identified by our literature search were included in the
meta-analysis when they met the following criteria: a) enrolment
of patients with intermediate or high-grade NHL; b) randomized
design; c) treatment assignment to a third generation regimen
(treatment group receiving either MACOP-B or m-BACOD or
ProMACE-CytaBOM or any other regimen defined as third
generation) or CHOP (control group); c) survival assessment (with
presentation of the survival graph). 
Our survival meta-analysis was carried out using individual
patient information (Stewart and Parmar, 1993; Jeng et al, 1995;
Oxman et al, 1995; Steinberg et al, 1997), i.e. survival length and
status at the last contact. In particular, the data of individual
survival were derived either from the original raw data provided
by the trial’s authors (who were contacted for this purpose) or
from the information contained in the figures that had originally
reported the survival graphs for these patients. 
After obtaining these survival data for all subjects enrolled in
the pertinent studies, our analysis generated a pooled survival
curve for third generation regimens and a pooled survival curve
for CHOP. In the survival comparison between the two treatments,
standard life-table methods (Kaplan-Meier analysis) and standard
techniques for univariate (log-rank test) or multivariate testing
(Cox model for multivariate relative risk estimation) were used.
When possible, the survival data were analysed using an intention-
to-treat approach. To construct the meta-analysis plot, crude death
rates from the individual studies (with their respective odds-ratios)
were pooled according to the grand-total method of Collins et al
(1985); in this way, the summary (or meta-analytic) odds-ratio of
death for the comparison between third generation regimens and
CHOP was estimated and presented in graphical form. 
In a secondary analysis, the meta-analytic comparison between
third generation regimens and CHOP was re-assessed using trial-
specific aggregate survival data, and so without construct-
ing patient-level information. The statistical method utilized for
this secondary analysis has been described previously (Messori
and Rampazzo, 1993) and reflects a traditional approach for
conducting a survival meta-analysis with no access to individual
patient data. Its application produced a meta-analytic odds-ratio of
death for third generation regimens vs. CHOP. 
RESULTS 
Clinical material 
5 trials (Table 1) met the inclusion criteria of our meta-analysis.
The total number of patients enrolled in these 5 trials was 1203 for
third generation regimens and 779 for CHOP. The crude survival
rates were 528/1203 (44%) for third generation regimens and
366/779 (47%) for CHOP. The third generation regimens used in
these trials included MACOP-B (n = 524; 44%), m-BACOD (n =
374; 31%), and ProMACE-CytaBOM (n = 305; 25%). The study
by Linch et al (1996) was excluded because the dose scheduling of
the CHOP regimen in the control group differed from the tradi-
tional 3-week administration (this study found no difference
between the third-generation regimen and CHOP). The scheduling
and dose intensity for the CHOP group was very similar across the
5 studies included in our analysis. 
The survival information for these patients was derived from: a)
Figure 2 for the study by Wolf et al (1997) (survival graphs based
on the intention-to-treat approach); b) Figure 2 for the study by
Fisher et al (1993) (survival graphs based on the intention-to-treat
approach); c) Figure 1 for the study by Gordon et al (1992) (by-
treatment analysis with no survival graph based on the intention-
to-treat approach); d) Figure 4 for the study by Montserrat et al
(1996) (survival graphs based on the intention-to-treat approach);
e) the original raw data of survival in the case of the study by
Jerkeman et al (1999) (data based on the intention-to-treat
approach excluding those patients who were randomized in the
absence of the inclusion criteria). 
In the 2 trials by Gordon et al (1992) and Wolf et al (1997), the
legends of the survival graphs provided complete information on
the time distribution of deaths and on the time distribution of right-
censored patients. In the 2 trials by Fisher et al (1993) and
by Montserrat et al (1996), the survival information was estim-
ated by the approximate procedure described in Appendix 1.
The individual survival times of the 1982 patients are not
presented herein, but have been published on the Internet site
http://members.nbci.com/sifotpn/supplements/NHL.htm/labsifo/
supplements/nh13g.htm. 
Survival meta-analysis 
Our survival meta-analysis yielded the two survival curves shown
in Figure 1. The survival rates (± standard error) for the third-
generation group were at 55.7% (± 1.5%) at 36 months, 53.7% (±
1.6%) at 48 months, 51.2% (± 1.6%) at 60 months, 49.1%
(± 1.7%) at 72 months; those for the CHOP group were 57.1% (±
1.9%) at 36 months, 53.3% (± 1.9%) at 48 months, 45.8%
(± 2.1%) at 60 months, 45.1% (± 2.1%) at 72 months. After 72
months, the number of patients at risk becomes relatively small,
and so the two curves are less informative. 
The survival difference between the two treatments was not
significant (chi-square by log-rank test with 1 df = 1.44, P = 0.23).
The Cox analysis (that considered the effect on survival of two
variables: ‘study’, introduced as a categorical variable stratified on
5 levels, and ‘treatment’ introduced as a categorical variable strat-
ified on 2 levels) calculated a relative death risk of 0.92 for third
generation regimens vs. CHOP (95% CI: 0.80 to 1.06; P = 0.26).
The study-specific values of relative death risk (Cox model) were
not significantly different from one another (study by Wolf et al
(1997): 1.00 with 95% CI of 0.86 to 1.17, P = 0.99; study by
Fisher et al (1993): 1.02 with 95% CI of 0.91 to 1.14, P = 0.76;
study by Montserrat et al (1996): 1.08 with 95% CI of 0.99 to 1.30,
P = 0.42; study by Jerkeman et al (1999): 0.91 with 95% CI of
0.78 to 1.05, P = 0.20; all risk values calculated in comparison
with the study by Gordon et al (1992) which was assumed to have
death risk = 1); these data show that the inter-trial heterogeneity of
the clinical material was acceptable. The meta-analysis plot based
on crude death rates is shown in Figure 2. 
In the meta-analysis based on aggregate survival data, the meta-
analytic odds-ratio of death for third generation regimens vs. CHOP
was 0.88 at 60 months (95% CI: 0.75 to 1.04; P = 0.15), which was
very close to the relative risk obtained from the meta-analysis of
individual patient data (0.92 with 95% CI of 0.80 to 1.06). 
DISCUSSION 
In our meta-analysis, the survival pattern for third generation regi-
mens was not significantly different from that of CHOP (Figure 1),
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two analyses of individual patient data) remained very far from 
the conventional level of statistical significance (P = 0.05). Hence, the
main conclusion resulting from our analysis is that third generation
regimens do not confer any survival benefit to NHL patients. The
results of our inter-study comparison based on the Cox model
showed that the heterogeneity across the 5 trials was not statis-
tically significant; this finding therefore supports the reliability of
our meta-analytical calculations. Among the 5 trials included in
our analysis (Table 1), there were 4 negative studies (Gordon et al,
1992; Fisher et al, 1993; Montserrat et al, 1996; Jerkeman et al,
1999) together with a single positive study (Wolf et al, 1997) that
found a survival improvement. The positive study has very similar
characteristics in comparison with the others in terms of both
patient selection criteria (very similar to the studies by Fisher et al
(1993) and Montserrat et al (1996)) and type of aggressive
chemotherapy (identical to the studies by Fisher et al (1993) and
Jerkeman et al (1999)). 
Since the 5 clinical trials examined in our study (Gordon et al,
1992; Fisher et al, 1993; Montserrat et al, 1996; Jerkeman et al,
1999; Wolf et al, 1997) do not show any significant advantage for
third generation chemotherapy in comparison with CHOP, our
results do not support the choice of third generation regimens as
the treatment for the control group that has been made in random-
ized studies testing new therapeutic approaches for NHL (e.g.
high-dose chemotherapy with haematopoietic stem cell rescue vs.
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Table 1 Patients included in the treatment group (third generation chemotherapy) and in the control group (CHOP) of the 5 RCTs 
Study Inclusion  Follow-up Treatment group Control group Survival comparison  Statistical level 
criteria length (y) between third generation  for the survival 
regimens vs. CHOP comparison 
No. of  Type of  No. of Type of 
patients chemotherapy patients chemotherapy* 
Cooper  Stage I–IV  9 125 MACOP-B 111 CHOP Crude rate of 63/125 for  P = 0.035 
et al  disease; MACOP-B vs. 68/111 for
(1994) intermediate CHOP; 5-y rate of 54% for 
and Wolf  or high grade MACOP-B vs. 41% for CHOP
et al  disorder; age
(1997) greater than 
16 years
Fisher  Stage II–IV  5 674 MACOP-B (n = 218§) 225 CHOP Crude death rate of 283/674 P = 0.90 
et al  disease;  or  for third generation vs. 88/225
(1993) intermediate m-BACOD  (n = 223 §) for CHOP; 3-y rate of  
or high grade  or 50% to 52% for third 
disorder;  ProMACE-CytaBOM generation vs. 54% 
no age  (n = 233 §) for CHOP
restrictions
Jerkeman  Stage II–IV  8 181 MACOP-B 193 CHOP 5-yr rate of 60% for P = NS 
et al  disease; high MACOP-B vs. 59% 
(1999) grade disorder;  for CHOP
age between 
18 and 67 
years
Gordon  Stage III–IV 6 151 m-BACOD 174 CHOP Crude death rate of 71/151 P = 0.489
et al  disease;  for m-BACOD vs. 91/174 for (by-treatment 
(1992) high grade  CHOP (by-treatment approach) approach) or 
disorder;  or 90/193 for m-BACOD vs.  P = 0.50 
no age  102/199 for CHOP (intention- (intention-to-
restrictions to-treat approach); treat approach)
5-y rate of 49% for
m-BACOD vs.
48% for CHOP
Montserrat  Stage II–IV 6 72 ProMACE-CytaBOM 76 CHOP Crude death rate of 40/72 P = NS 
et al  disease; for third generation
(1996) intermediate  vs. 
or high grade  38/76 for CHOP; 5-y rate of
disorder; 42% in both groups
no age 
restrictions
§ In our analysis, these 3 different third-generation schemes were pooled into a single treatment group (n = 674) which was compared to the control group (225
patients given CHOP). *The two studies by Gordon et al and Jerkeman et al administered at least 8 cycles of CHOP in responders, while the two studies of
Montserrat et al and Cooper et al administered at least 6 cycles (together with the criterion of 2 cycles after complete response for the study of Cooper); Fisher
et al administered 8 cycles of CHOP (unless progressive disease developed). NS = not significant. a third-generation regimen (Gianni et al, 1997) or comparison of
two third-generation regimens with one another (Mazza et al,
1995; Guglielmi et al, 1989)). Nonetheless, the fact that the control
group of these trials received third generation regimens (instead of
CHOP), discloses a quite widespread, though unproven, belief that
these regimens are more effective, at least in certain subsets of
NHL patients (e.g. young subjects who are thought to better
tolerate the full doses of third generation regimens). Although one
(Wolf et al, 1997) of the 5 clinical studies found that the survival
advantage resulting from third generation regimens was restricted
to the subset of younger patients (and was instead much smaller in
older subjects), the other 4 studies did not confirm this finding or
did not specifically address this hypothesis. Hence, this question
remains open and cannot be settled by the results of our analysis. 
In comparing third-generation regimens with CHOP, our
analysis showed that the relative death risk was 0.92 and that the
95% CI for this relative risk ranged from 0.80 to 1.06. Hence, our
findings are compatible (at the 5% level) with the hypothesis that
third-generation regimens are 20% better than CHOP in relative
terms, but are also compatible with the hypothesis that CHOP is
6% better than third-generation regimens. If new studies will be
designed to test again the hypothesis that third-generation regi-
mens improve survival (according to our data, the survival
improvement is, in absolute terms, from 45.1% to 49.1% at 72
months with a relative difference of +8%), their sample size
should be of at least 2360 patients for the third-generation
regimen group and 2360 patients for the CHOP group (statistical
power calculations made using the method of Edmiston et al
(1993) with alpha = 0.10 (two-tailed) and (1-beta) = 0.80). If
these studies are aimed at detecting a relative survival improve-
ment of +10%, +15% or +20%, the suggested sample size for
each of the two study arms reduces to 1514 patients, 664 patients
or 379 patients, respectively. In the light of these statistical power
calculations, planning new controlled studies on this issue will
require a patient population of this size, but one could wonder
whether such experimental effort is worthwhile. In any case, new
studies based on small patient populations would make little
sense because they would be bound to generate no useful results.
Fisher et al (1993) have shown that the cost of third generation
regimens can vary considerably, but is always much higher than
that of CHOP. According to Fisher, if the cost of the drugs used in
a planned course of CHOP is assigned a value of 1.00, the cost of
MACOP-B is 1.13, that of ProMACE-CytaBOM 1.44, and that of
m-BACOD is 2.26 (on the basis of average wholesale prices of
US in 1993). A more complete economic analysis would imply
the assessment of the costs of hospitalization and day hospital,
which are known to be much higher for third-generation regimens
than for CHOP, and so this would greatly enhance the cost
difference between the two treatments. While a specific cost-
effectiveness calculation would require a separate study, this
preliminary information on costs and clinical benefits favours
CHOP with a quite clear indication due to a lower cost per patient
and similar therapeutic efficacy in comparison with third-genera-
tion regimens. 
The main difference between CHOP and the third-generation
regimens is the number of chemotherapeutic drugs. In m-BACOD
and MACOP-B, methotrexate and bleomycin was added to the
drugs in CHOP. In addition, the ProMACE-CytaBOM regimen
included etoposide and cytarabine. The rationale was to overcome
chemotherapy resistance and improve curability by addition of
non-crossresistant drugs, in line with the hypothesis by Goldie et
al (1982). However, to avoid excess toxicity, the dose intensity
(DI) of cyclophosphamide and doxorubicin had to be reduced in
the newer regimens, with the exception of a slightly higher DI of
doxorubicin in MACOP-B. 
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Figure 1 Survival in patients with intermediate or high-grade NHL: the solid
curve shows the survival pattern for patients treated with third generation
regimens (n = 1203), while the dashed curve refers to patients treated with
CHOP (n = 779). Both curves were calculated by standard life-table methods
using individual patient data. In the third-generation group, the number of
patients at risk was 590 at 24 months, 386 at 48 months, 111 at 72 months,
and 12 at 96 months; the same figures for the CHOP group were 377, 240,
83 and 13, respectively. See text for details 
Figure 2 Comparison of crude death rates between third-generation
regimens and CHOP: values of study-specific odds-ratio (circles) with 95%
CIs and summary odds-ratio (diamond) with 95% CI. The vertical dotted line
represents identity in death rate between the two patient groups. From top to
bottom, the first 5 data sets show the study-specific odds-ratio for the trial of
Gordon et al, Wolf et al, Fisher et al, Montserrat et al and Jerkeman et al,
respectively; the sixth data set shows the results of our meta-analysis
(summary odds-ratio). The two graph sections that favour 3GRs (left) or
CHOP (right) are presented according to the standard scheme of meta-
analysis graphs. Abbreviations: 3GRs = third generation regimens In light of the present analysis, one may conclude that addition
of bleomycin and methotrexate is insufficient to overcome
chemotherapy resistance, and that the drugs included in the CHOP
regimen (cyclophosphamide, doxorubicin and vincristine)
are more important for therapeutic efficacy. In the design of future
studies, if one accepts the view that further testing of third-
generation based on very large-scale studies is not worthwhile,
alternative approaches should be sought, such as further escalation
of doxorubicin and cyclophosphamide. 
APPENDIX 1: APPROXIMATIONS INTRODUCED
IN OUR SURVIVAL ANALYSIS 
In our analysis of the trials by Fisher et al (1993) and Montserrat
et al (1996), each of the two survival curves (treatment group and
controls) was analysed by the approximate method described by
Fine et al (1993) in order to convert the aggregate survival data
that had originally been published in graphical form into values of
individual survival. This method determines the distribution over
time of deaths and of terminations of follow-up (i.e. cases of right
‘censored patients’) using a graphical analysis of the published
curves. The calculation requires also the knowledge of the total
number of patients and the total number of deaths (reported sepa-
rately for the two arms of the study under examination), which
were both directly presented in the text of the two articles. 
This approximated method for constructing individual survival
times has often been used in previous retrospective overviews and
in meta-analyses of survival data (Fine et al, 1993; Messori et al,
1994; Bardelli et al, 1995; Trallori et al, 1995; Ferradina et al,
1997; Messori et al, 1999a, 1999b). The computer programme
implementing this method has been recently published (Messori 
et al, 2000).
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